Medifast Inc · NYSE:MED
Medifast — Q1 2025 Earnings Presentation
15 slides from Medifast's earnings presentation, Apr 28, 2025
Slide 1: Medifast Q1 2025 Earnings Supplement
Medifast® Q1 2025 Earnings Supplement © 2025 Medifast, Inc. All Rights Reserved.
Slide 2: Forward-looking statements
2 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally
Slide 3: Q1 2025 highlights
3 Revenue and EPS in upper end of guidance range Gross profit margin of 72.8% was unchanged versus Q1 2024 Operating margin declined primarily from loss of leverage of fixed costs on lower volumes Coach trends continued to improve • Revenue per active earning coach (AEC) declined 1.4% Y/Y • New coac
Slide 4: Q1 2025 By The Numbers
4 $116M ($1.3M) ($0.07) REVENUE OPERATING LOSS LOSS PER SHARE Q1 2025 By The Numbers $4,556 25,400 $165M REVENUE PER ACTIVE ACTIVE EARNING CASH & CASH EQUIVALENTS EARNING COACH COACHES AND INVESTMENTS © 2025 Medifast, Inc. All Rights Reserved.
Slide 5: Building the health and wellness company of the future
5 Offering integrated Expanding focus Building the health and wellness lifestyle solutions that more to help customers in various company of the future, designed uniquely reflect the needs of need-states, with or without to thrive in a GLP-1 world the consumer than medications any other offering tod
Slide 6: Offers are for…
6 Those who don’t want to use GLP-1 medications to support their weight loss Offers Those using GLP-1 medications as a core element are for… of their weight loss program Those seeking to maintain the weight loss they have achieved, regardless of whether they used GLP-1 medication to achieve it or ac
Slide 7: Long-term GLP-1 trial weight change data
7 12% 74% Data from long-term tirzepatide (176 weeks) and semaglutide (221 weeks) clinical trials showing changes in body weight from baseline (% change) *Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without over time (weeks). Figure recreated from
Slide 8: Weight regain after GLP-1 medication withdrawal
8 68 Weeks 52 Weeks 0 Treatment Phase Off-treatment Phase Post-GLP-1 Medication -2 Body weight (%) – change from baseline -4 After medication withdrawal, -6 body weight regain was observed -8 -10 Participants -12 regained two-thirds -14 of prior weight loss Placebo -16 Semaglutide Ongoing manageme
Slide 9: Scientifically-Developed Food Choices, Community, Coaching
10 Scientifically-Developed Lower Food Fills Nutrient Food Choices Volume Options Inadequacies • Plans for GLP-1 med users and • OPTAVIA ASCEND is under Dietary non-med users who want support 230 calories per serving supplementation managing their weight • ~20g of protein per eating (Multivitamin &
Slide 10: OPTAVIA Coaches Set Medifast Apart
OPTAVIA ® Coaches Set Medifast Apart ® OPTAVIA champions people who are navigating weight loss at different moments in life, providing unparalleled coaching support along with community, nutrition and healthy habits. The holistic approach empowers people to master their weight loss journey through e
Slide 11: Coach opportunities, tactics and results
12 Opportunities Tactics Results Elevate coach On-going education Self-guided training, including new podcasts with education and and related support outside subject matter experts, and best training for new GLP- infrastructure practices shared by top performing coaches, to Almost 50% of coaches hav
Slide 12: Introduction of OPTAVIA EDGE Program
Introduction of OPTAVIA EDGE Program Field-wide recognition and duplication system designed to drive coach productivity, increase customer acquisition and coach sponsorship, and improve leadership development Clear tiered structure 4 achievement levels with progressive business-building behaviors &
Slide 13: 2024 Accomplishments and Look Ahead to 2025
14 2024 Accomplishments Look Ahead To 2025 • Fuel For The Future actions taken • Targeting $15M to $20M in additional savings in included reducing distribution footprint, 2025 in total for the entire organization optimizing procurement efforts, and utilizing more automated customer interaction • Ini
Slide 14: 2025 strategic priorities
15 Accelerate customer acquisition • Utilize enhanced coach-driven efforts supplemented by company-led marketing • Attract new customers and reactivate lapsed participants Improve coach productivity • Roll out of EDGE coach leadership development program • Scale best practices of high-performing tea
Slide 15: Q2 2025 Guidance
16 $85M - $105M ($0.55) - $0.00 Q2 Revenue Q2 earnings per share Q2 2025 Excludes any gains or losses from changes in the market price of the Company’s Guidance LifeMD common stock investment © 2025 Medifast, Inc. All Rights Reserved.